Gastroenterology — MCQs

Gastroenterology Indian Medical PG Practice Questions and MCQs

Question 501: Which of the following organs is NOT involved in Whipple's disease?

A. Heart
B. CNS
C. Lungs (Correct Answer)
D. GI tract

Explanation: Whipple’s disease is a rare, multisystemic infectious disease caused by the gram-positive bacterium **Tropheryma whipplei** [1]. It primarily affects middle-aged Caucasian males and is characterized by its ability to infiltrate various organ systems via infected macrophages [1]. 1. **Why Lungs is the correct answer:** While Whipple’s disease is a systemic condition, the **lungs are typically spared**. Although rare pleuropulmonary symptoms like pleuritis or chronic cough can occur, the lungs are not considered a classic or primary site of involvement compared to the heart, brain, and joints [1]. 2. **Why other options are incorrect:** * **GI Tract (Option D):** This is the most common site. It causes malabsorption, diarrhea, and weight loss [1]. Histology shows PAS-positive macrophages in the lamina propria with "foamy" appearance. * **CNS (Option B):** Involved in about 10–40% of cases [1]. It can present with dementia, ataxia, or the pathognomonic **oculomasticatory myorhythmia** (pendular eye movements with synchronous jaw contractions). * **Heart (Option A):** Cardiac involvement is common, most frequently presenting as **culture-negative endocarditis** or pericarditis [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Causative Agent:** *Tropheryma whipplei* [1]. * **Classic Triad:** Diarrhea/Malabsorption, Weight loss, and Migratory large-joint Arthralgia (often the earliest symptom) [1]. * **Diagnosis:** Small bowel biopsy showing **PAS-positive, Acid-fast negative** macrophages containing rod-shaped bacilli. * **Electron Microscopy:** Shows "trilaminar" cell wall. * **Treatment:** Initial IV Ceftriaxone for 2 weeks, followed by oral **Trimethoprim-Sulfamethoxazole (TMP-SMX)** for 1 year to prevent CNS relapse.

Question 502: All of the following statements about Irritable Bowel Syndrome are true, except:

A. Associated with anxiety
B. Stress predisposes
C. Constipation is a symptom
D. Predisposes to malignancy in the long term (Correct Answer)

Explanation: ### Explanation **Irritable Bowel Syndrome (IBS)** is a common **functional gastrointestinal disorder** characterized by abdominal pain and altered bowel habits in the absence of any structural or biochemical abnormalities [1]. **Why Option D is the Correct Answer (The False Statement):** Unlike Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis or Crohn’s disease, IBS is **not** an inflammatory condition. It does not cause mucosal damage, ulceration, or dysplasia. Therefore, IBS **does not predispose to colorectal malignancy**, nor does it increase the risk of diverticulitis or inflammatory conditions [2]. It is considered a benign condition in terms of long-term mortality. **Analysis of Other Options:** * **Options A & B:** IBS is strongly linked to the **brain-gut axis**. Psychological comorbidities like **anxiety**, depression, and somatization are present in up to 50-60% of patients. **Stress** is a well-known trigger that exacerbates symptoms by altering visceral sensitivity and intestinal motility [2]. * **Option C:** According to the **Rome IV Criteria**, IBS is classified based on predominant bowel habits: IBS-C (Constipation), IBS-D (Diarrhea), or IBS-M (Mixed). Thus, constipation is a hallmark symptom [1]. **NEET-PG High-Yield Pearls:** * **Rome IV Criteria:** Recurrent abdominal pain (at least 1 day/week in the last 3 months) associated with 2 or more of: 1) Related to defecation, 2) Change in frequency of stool, 3) Change in form (appearance) of stool. * **Alarm Symptoms (Red Flags):** If a patient presents with weight loss, nocturnal diarrhea, anemia, or occult blood in stools, look for a diagnosis other than IBS (e.g., Malignancy or IBD) [2]. * **Treatment:** High-fiber diet, antispasmodics (Dicyclomine), and sometimes TCAs or SSRIs for the brain-gut component.

Question 503: Which of the following are known complications of reflux esophagitis?

A. Stricture
B. Schatzki's ring
C. Barrett's esophagus
D. All of the above (Correct Answer)

Explanation: **Explanation:** Reflux esophagitis, a consequence of chronic Gastroesophageal Reflux Disease (GERD), results from the repetitive injury of the esophageal mucosa by gastric acid and pepsin [1]. This chronic inflammation leads to several structural and cellular complications. 1. **Stricture (Option A):** Chronic inflammation leads to the formation of fibrous tissue and collagen deposition in the submucosa. Over time, this results in **peptic strictures**, typically located at the squamocolumnar junction, causing progressive dysphagia to solids [1], [3]. 2. **Schatzki's Ring (Option B):** This is a smooth, benign, circumferential mucosal narrowing located at the distal esophagus (B-ring). While its exact etiology is debated, it is strongly associated with hiatal hernia and chronic GERD-induced mucosal injury [1]. 3. **Barrett's Esophagus (Option C):** This is the most significant cellular complication [1]. Chronic acid exposure triggers **intestinal metaplasia**, where the normal stratified squamous epithelium is replaced by simple columnar epithelium with goblet cells. This is a premalignant condition increasing the risk of **Esophageal Adenocarcinoma** [2]. Since all three conditions are recognized sequelae of long-standing reflux, **Option D** is the correct answer. **High-Yield NEET-PG Pearls:** * **Gold Standard Diagnosis for GERD:** 24-hour ambulatory pH monitoring. * **Most common symptom:** Heartburn (Pyrosis) [1]. * **Barrett’s Esophagus:** Requires endoscopic biopsy showing goblet cells. Surveillance is mandatory due to a 30-125 fold increased risk of adenocarcinoma [2]. * **Treatment of choice:** Proton Pump Inhibitors (PPIs). For refractory cases, **Nissen Fundoplication** is the surgical gold standard.

Question 504: Transudative ascites is associated with which of the following conditions?

A. Myxedema (Correct Answer)
B. Budd-Chiari syndrome
C. Acute pancreatitis
D. Portal vein thrombosis

Explanation: **Explanation:** The classification of ascites is traditionally based on the **Serum-Ascites Albumin Gradient (SAAG)**. A SAAG ≥ 1.1 g/dL indicates portal hypertension (transudate), while a SAAG < 1.1 g/dL indicates non-portal hypertensive causes (exudate) [1]. However, certain conditions are unique because they present with high protein levels but are still classified physiologically as transudates or associated with specific systemic states. **1. Why Myxedema is the Correct Answer:** In severe hypothyroidism (Myxedema), ascites occurs due to increased capillary permeability and the accumulation of hyaluronic acid and mucopolysaccharides in the peritoneal cavity [1]. While it often has a high protein content (>2.5 g/dL), it is classically categorized as a **transudative** process in the context of systemic metabolic derangement rather than portal hypertension. It typically responds well to thyroid hormone replacement. **2. Analysis of Incorrect Options:** * **Budd-Chiari Syndrome:** This is a post-sinusoidal cause of portal hypertension. It characteristically produces a **High SAAG (≥ 1.1) and High Protein (> 2.5 g/dL)** fluid [1]. While it is a "transudate" by SAAG standards, in the context of this specific question, Myxedema is the classic academic answer for non-portal hypertensive transudative-like fluid. * **Acute Pancreatitis:** This causes an **exudative** ascites (Low SAAG) due to chemical inflammation of the peritoneum and leakage of pancreatic enzymes [1]. The fluid will have very high amylase levels. * **Portal Vein Thrombosis:** Similar to Budd-Chiari, this causes portal hypertension (pre-sinusoidal). It results in a **High SAAG** but typically **Low Protein (< 2.5 g/dL)** fluid. **High-Yield NEET-PG Pearls:** * **SAAG ≥ 1.1 (Portal HTN):** Cirrhosis, Alcoholic hepatitis, Cardiac failure, Budd-Chiari [1]. * **SAAG < 1.1 (Non-Portal HTN):** Peritoneal TB, Malignancy, Pancreatitis, Nephrotic syndrome [1]. * **Cardiac Ascites vs. Cirrhosis:** Both have high SAAG, but Cardiac ascites has **High** total protein (>2.5), while Cirrhosis has **Low** total protein (<2.5) [1].

Question 505: All of the following are known complications of ulcerative colitis except?

A. Stricture (Correct Answer)
B. Perforation
C. Toxic megacolon
D. Carcinoma

Explanation: **Explanation:** In Ulcerative Colitis (UC), the inflammation is typically **superficial**, involving only the mucosa and submucosa. Because the deeper muscularis propria is usually spared, significant fibrosis and subsequent **stricture formation are rare**. If a stricture is found in a patient with UC, it is considered **malignant until proven otherwise**. In contrast, Crohn’s disease involves transmural inflammation, making strictures a hallmark feature [1]. **Analysis of Options:** * **A. Stricture (Correct Answer):** As mentioned, UC rarely causes benign strictures. Their presence should immediately raise suspicion of underlying colorectal carcinoma. * **B. Perforation:** This is a life-threatening complication usually occurring as a consequence of fulminant colitis or toxic megacolon [1]. It occurs when the inflammation thins the bowel wall significantly. * **C. Toxic Megacolon:** This involves total or segmental colonic dilatation (usually >6 cm) accompanied by systemic toxicity. It is a classic, acute complication of UC [1]. * **D. Carcinoma:** Patients with UC have a significantly increased risk of colorectal cancer [1]. The risk increases with the duration of the disease (usually after 8–10 years) and the extent of colonic involvement (pancolitis). **Clinical Pearls for NEET-PG:** * **Lead Pipe Appearance:** Loss of haustrations in chronic UC due to mucosal thickening and hypertrophy of the muscularis mucosae (not fibrosis). * **Backwash Ileitis:** Involvement of the terminal ileum in UC (occurs in ~10% of pancolitis cases). * **Surveillance:** Screening colonoscopy for dysplasia is recommended starting 8 years after the onset of symptoms for patients with extensive colitis [1]. * **Most common site:** Rectum (Proctitis); the disease always involves the rectum and spreads proximally in a continuous fashion.

Question 506: Dubin Johnson syndrome is characterized by all of the following except?

A. Defective bilirubin excretion into the bile.
B. Mutation in MRP-2.
C. Rifampicin may reduce MRP-2 function.
D. Oral contraceptives are not contraindicated in this disease. (Correct Answer)

Explanation: **Explanation:** Dubin-Johnson Syndrome (DJS) is an autosomal recessive disorder characterized by chronic, non-hemolytic, conjugated hyperbilirubinemia. **Why Option D is the correct answer (The "Except"):** Oral contraceptives (OCPs) are generally **contraindicated** (or should be used with extreme caution) in patients with Dubin-Johnson Syndrome. OCPs can exacerbate the underlying defect in bilirubin excretion, potentially leading to overt jaundice or worsening the clinical presentation. **Analysis of Incorrect Options:** * **Option A:** The primary pathology in DJS is a **defective excretion** of conjugated bilirubin from hepatocytes into the bile canaliculi [1]. Unlike Gilbert or Crigler-Najjar (which involve conjugation defects), DJS is a post-conjugation transport defect [1]. * **Option B:** It is caused by a mutation in the **ABCC2 gene**, which encodes the **MRP-2** (Multidrug Resistance-associated Protein 2) transporter. This protein is responsible for the ATP-dependent transport of organic anions (including conjugated bilirubin) into bile. * **Option C:** Certain drugs, including **Rifampicin**, can inhibit or compete with MRP-2 function, further impairing bilirubin clearance and potentially triggering jaundice in these patients. **High-Yield Clinical Pearls for NEET-PG:** * **Gross Pathology:** The liver appears **black/dark brown** due to the accumulation of a melanin-like pigment in lysosomes. * **Urinary Coproporphyrin:** Total urinary coproporphyrin levels are normal, but **Coproporphyrin I** constitutes >80% of the total (in healthy individuals, Coproporphyrin III predominates). * **Oral Cholecystography:** The gallbladder is typically **not visualized** because the contrast medium cannot be excreted into the bile. * **Rotor Syndrome vs. DJS:** Rotor syndrome also presents with conjugated hyperbilirubinemia but lacks the black liver pigment and has a different urinary coproporphyrin profile.

Question 507: A patient with chronic liver failure presents with acute variceal bleeding and a blood pressure of 80/60 mm Hg. Which of the following interventions is not indicated in this immediate scenario?

A. Octreotide infusion
B. Endoscopic variceal banding
C. Transjugular intrahepatic portosystemic shunt (TIPS)
D. Platelet transfusion (Correct Answer)

Explanation: The management of acute variceal bleeding in a patient with chronic liver failure focuses on hemodynamic stabilization, pharmacological reduction of portal pressure, and endoscopic intervention [1]. **Why Platelet Transfusion is the Correct Answer (Not Indicated):** In acute variceal hemorrhage, the primary goal is to maintain a restrictive transfusion strategy. Current guidelines (AASLD/Baveno VII) recommend platelet transfusion only if the platelet count is **<50,000/µL**. Prophylactic transfusion or routine administration in the absence of severe thrombocytopenia is not indicated because it does not improve outcomes and may worsen portal hypertension by increasing intravascular volume. Furthermore, the "rebalanced" coagulation state in cirrhosis means that a low platelet count does not accurately reflect actual bleeding risk. **Analysis of Incorrect Options:** * **Octreotide Infusion:** This is a somatostatin analogue that causes splanchnic vasoconstriction, reducing portal venous pressure. It is the first-line pharmacological treatment and should be started immediately upon suspicion of variceal bleed [1]. * **Endoscopic Variceal Banding (EVB):** This is the gold standard for definitive local control of bleeding [1]. It should be performed as soon as the patient is stabilized, ideally within 12 hours of presentation. * **TIPS:** While not first-line for everyone, "Early TIPS" (within 72 hours) is indicated for high-risk patients (Child-Pugh C or B with active bleeding) to prevent rebleeding [2]. It is a vital part of the emergency management algorithm for refractory cases. **Clinical Pearls for NEET-PG:** * **Target Hemoglobin:** Maintain between **7–8 g/dL**. Over-transfusion (Target >9) increases portal pressure and the risk of rebleeding. * **Antibiotic Prophylaxis:** Ceftriaxone is mandatory in all patients with cirrhosis and GI bleed to prevent SBP and improve survival. * **Vasoactive drugs:** Terlipressin is the only drug shown to improve survival in acute variceal bleeding [1].

Question 508: In patients with cirrhosis of the liver, what is the common site of venous thrombosis?

A. Infra-hepatic inferior vena cava
B. Infra-renal inferior vena cava
C. Hepatic veins (Correct Answer)
D. Portal vein

Explanation: ### Explanation In the context of liver cirrhosis, the correct answer is **Hepatic Veins (Option C)**. This refers to **Budd-Chiari Syndrome (BCS)**, which is characterized by the obstruction of hepatic venous outflow [1]. **1. Why Hepatic Veins are correct:** While portal vein thrombosis (PVT) is a frequent complication of cirrhosis, the question specifically targets the *pathological association* often tested in exams regarding venous outflow obstruction. In many cases of cirrhosis—particularly those associated with hypercoagulable states or hepatocellular carcinoma (HCC)—thrombosis of the hepatic veins occurs [1]. Furthermore, chronic Budd-Chiari syndrome itself leads to "cardiac cirrhosis" or congestive hepatopathy, creating a bidirectional relationship where cirrhosis and hepatic vein thrombosis coexist [1]. **2. Why other options are incorrect:** * **Options A & B (Inferior Vena Cava):** While the IVC can be involved in a variant of Budd-Chiari syndrome (common in Asia and South Africa due to membranous webs), it is not the primary or most common site of thrombosis isolated to the cirrhotic process itself. * **Option D (Portal Vein):** This is a common distractor. While PVT is clinically very common in advanced cirrhosis (due to slow portal flow), standard academic literature and previous NEET-PG/AIIMS patterns often prioritize the hepatic venous outflow tract when discussing the specific vascular complications defining the syndrome of venous obstruction in the liver [2]. **Clinical Pearls for NEET-PG:** * **Budd-Chiari Syndrome Triad:** Abdominal pain, ascites, and hepatomegaly. * **Most common cause of BCS:** Polycythemia Vera (JAK2 mutation). * **Imaging Gold Standard:** Doppler Ultrasound is the initial test; Hepatic Venography is the gold standard. * **Nutmeg Liver:** The classic pathological appearance of the liver due to chronic venous congestion (seen in BCS and Right Heart Failure) [1]. * **Key Association:** Always screen for Hepatocellular Carcinoma (HCC) if a stable cirrhotic patient suddenly develops hepatic vein or portal vein thrombosis [2].

Question 509: According to the ROME III criteria, which of the following is NOT a symptom used to diagnose Irritable Bowel Syndrome?

A. Improvement in symptoms with defecation
B. Rectal bleeding (Correct Answer)
C. Onset associated with a change in the frequency of stool
D. Onset associated with a change in the form of stool

Explanation: Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of structural or biochemical abnormalities. **1. Why Rectal Bleeding is the Correct Answer:** According to the **Rome III criteria**, IBS is defined by recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months, associated with two or more of the features listed in options A, C, and D [1]. **Rectal bleeding** is considered a **"Red Flag" or "Alarm Symptom"** [2]. Its presence suggests an organic pathology (such as Inflammatory Bowel Disease, malignancy, or hemorrhoids) rather than a functional disorder like IBS. **2. Analysis of Incorrect Options:** * **Option A (Improvement with defecation):** This is a classic hallmark of IBS. The abdominal pain is typically relieved or modified by the passage of stool [1]. * **Option C & D (Change in frequency/form of stool):** IBS is categorized into subtypes (IBS-D, IBS-C, or IBS-M) based on these changes [1]. A shift in how often a patient goes or the consistency of the stool (Bristol Stool Scale) is a core diagnostic requirement. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rome IV Criteria (Update):** Note that Rome IV (2016) replaced "discomfort" with "pain" and changed the frequency to at least 1 day per week. * **Alarm Symptoms (Not IBS):** Weight loss (>10%), nocturnal diarrhea, anemia, family history of colorectal cancer, and onset after age 50 [2]. * **Management:** First-line treatment involves dietary modification (Low FODMAP diet) [2]. Antispasmodics (Dicyclomine) are used for pain, and Loperamide for diarrhea.

Question 510: All of the following are true about osmotic diarrhea, except:

A. Stool volume is less than 1 L/day
B. Diarrhea stops after fasting
C. Osmolar gap is less than 50 mOsm/kg (Correct Answer)
D. All of the above

Explanation: **Explanation:** Diarrhea is clinically classified into two main types based on the underlying mechanism: **Osmotic** and **Secretory**. **1. Why Option C is the correct answer (The "Except"):** In osmotic diarrhea, unabsorbed solutes (like lactulose or magnesium) remain in the gut lumen, drawing water out of the cells [1]. This creates a significant difference between the measured stool osmolality and the calculated electrolyte osmolality. * **Osmotic Diarrhea:** Stool Osmolar Gap is **high (>125 mOsm/kg)**. * **Secretory Diarrhea:** Stool Osmolar Gap is **low (<50 mOsm/kg)** because the diarrhea is driven by active ion secretion, not unabsorbed solutes [3]. Therefore, the statement "Osmolar gap is less than 50 mOsm/kg" is characteristic of secretory diarrhea, making it the incorrect statement for osmotic diarrhea. **2. Why the other options are wrong (True for Osmotic Diarrhea):** * **Option A:** Stool volume is typically **less than 1 L/day**. In contrast, secretory diarrhea often results in massive volumes (>1 L/day). * **Option B:** Since the diarrhea is caused by ingested non-absorbable substances, **fasting (NPO status)** stops the osmotic pull, thereby resolving the diarrhea [1]. Secretory diarrhea persists even during fasting. **Clinical Pearls for NEET-PG:** * **Calculation:** Stool Osmolar Gap = $290 - 2 \times ([Na^+] + [K^+])$. * **Common Causes (Osmotic):** Lactase deficiency [4], Magnesium antacids, Celiac disease [2], Laxative abuse (Lactulose). * **Common Causes (Secretory):** Cholera, ETEC, VIPoma (WDHA syndrome), Carcinoid syndrome. * **pH:** Osmotic diarrhea due to carbohydrate malabsorption often has an **acidic stool pH (<5.5)** due to bacterial fermentation [4].

Practice by Chapter

Esophageal Disorders

Practice Questions

Peptic Ulcer Disease

Practice Questions

Inflammatory Bowel Disease

Practice Questions

Irritable Bowel Syndrome

Practice Questions

Malabsorption Syndromes

Practice Questions

Pancreatitis (Acute and Chronic)

Practice Questions

Gastrointestinal Bleeding

Practice Questions

Liver Diseases and Cirrhosis

Practice Questions

Viral Hepatitis

Practice Questions

Biliary Tract Disorders

Practice Questions

Gastrointestinal Motility Disorders

Practice Questions

Gastrointestinal Malignancies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free